Review
Oncology
Iva Truxova, David Cibula, Radek Spisek, Jitka Fucikova
Summary: Epithelial ovarian cancer (EOC) ranks among the top causes of cancer-related death in women due to early dissemination of malignant cells to the peritoneum. Despite improvements in medical therapies, EOC remains insensitive to immune checkpoint inhibitors, mainly due to a tumor microenvironment characterized by poor immune cell infiltration and immune suppression by tumor-associated macrophages (TAMs). TAMs have emerged as potential therapeutic targets to reverse immunosuppression and enhance the effectiveness of immunotherapy. This review focuses on the biological features of TAMs and their relevance as targets for treating EOC, including therapies that modulate TAM recruitment, polarization, survival, and function in the EOC tumor microenvironment for better combinatorial regimens with immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Celia Martin-Otal, Aritz Lasarte-Cia, Diego Serrano, Noelia Casares, Enrique Conde, Flor Navarro, Ines Sanchez-Moreno, Marta Gorraiz, Patricia Sarrion, Alfonso Calvo, Carlos E. De Andrea, Jose Echeveste, Amaia Vilas, Juan Roberto Rodriguez-Madoz, Jesus San Miguel, Felipe Prosper, Sandra Hervas-Stubbs, Juan Jose Lasarte, Teresa Lozano
Summary: This study demonstrates the feasibility and efficacy of targeting the tumor-specific fibronectin splice variant EDA with CAR-T cells, providing a potential therapeutic option for different types of cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Ge Gao, Weiting Liao, Pei Shu, Qizhi Ma, Xia He, Benxia Zhang, Diyuan Qin, Yongsheng Wang
Summary: This study identified the association of S1PR3 high expression with T-cell exhaustion and immunotherapy resistance, and explored the potential of combining S1PR3 antagonist with CAR-T cell therapy, achieving significant efficacy in mouse models of breast cancer and colon cancer. These findings provide a rationale for the combination of S1PR3 inhibitor and CAR-T cells in the treatment of solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Luan Sun, Fang Gao, Zhanhui Gao, Lei Ao, Na Li, Sujuan Ma, Meng Jia, Nan Li, Peihua Lu, Beicheng Sun, Mitchell Ho, Shaochang Jia, Tong Ding, Wei Gao
Summary: This study constructed two types of CAR-T cells targeting different epitopes of GPC3 to investigate the influence of sGPC3 on the activation and cytotoxicity of CAR-T cells in vitro and in vivo. Results showed that sGPC3 significantly inhibited the release of cytokines and the cytotoxicity of anti-GPC3 CAR-T cells in vitro, and in mouse models sGPC3 expression in Hep3B xenograft tumors led to a worse response to CAR-T cell treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Catherine M. Ade, Matthew J. Sporn, Sudipto Das, Zhiya Yu, Ken-ichi Hanada, Yue A. Qi, Tapan Maity, Xu Zhang, Udayan Guha, Thorkell Andresson, James C. Yang
Summary: This article introduces a method of using mass spectrometry to identify common tumor-specific neoepitopes derived from mutated oncogenes, and develop TCRs based on these data. The results of the study show that this method successfully identified precise neoepitopes derived from KRAS, EGFR, BRAF, and PIK3CA presented by HLA-A*03:01 and/or HLA-A*11:01 across multiple biological replicates.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Loic Reppel, Ourania Tsahouridis, Jason Akulian, Ian J. Davis, Hong Lee, Giovanni Fuca, Jared Weiss, Gianpietro Dotti, Chad Pecot, Barbara Savoldo
Summary: This study suggests that GD2 is a promising target for CAR-T cell therapy in lung cancer, and the use of tazemetostat can upregulate GD2 expression in tumor cells, enhancing their susceptibility to CAR-T cell targeting.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Chemistry, Multidisciplinary
Valeria Ukrainskaya, Yuri Rubtsov, Dmitry Pershin, Nadezhda Podoplelova, Stanislav Terekhov, Igor Yaroshevich, Anstasiia Sokolova, Dmitry Bagrov, Elena Kulakovskaya, Victoria Shipunova, Sergey Deyev, Rustam Ziganshin, Aleksandr Chernov, Georgii Telegin, Eugene Maksimov, Oleg Markov, Anastasiya Oshchepkova, Marina Zenkova, Jia Xie, Hongkai Zhang, Alexander Gabibov, Michael Maschan, Alexey Stepanov, Richard Lerner
Summary: The development of CAR-T therapy has achieved success in the treatment of B cell leukemia, but the expansion of CAR-T cells remains challenging with current protocols. A novel approach using cell-derived membrane vesicles has been proposed, showing greater potential in stimulating, proliferating, and enhancing the functional activity of CAR-T cells.
Review
Pharmacology & Pharmacy
Guidong Zhu, Qing Zhang, Junwen Zhang, Fusheng Liu
Summary: CAR-T therapy shows promising results in treating blood cancers, particularly leukemia, but its effectiveness for solid tumors like glioblastoma is limited. The immunosuppressive microenvironment of malignant gliomas hinders CAR-T therapy and restricts its efficacy, despite ongoing research efforts to enhance its potential clinical applications.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Diana Rose E. Ranoa, Preeti Sharma, Claire P. Schane, Amber N. Lewis, Edward Valdez, Venkata V. V. R. Marada, Marlies Hager, Will Montgomery, Steven P. Wolf, Karin Schreiber, Hans Schreiber, Keith Bailey, Timothy M. Fan, Paul J. Hergenrother, Edward J. Roy, David M. Kranz
Summary: The use of CAR-T cell therapy against blood cancers has been successful, but its efficacy against solid tumors has been limited. By using a mouse ovarian cancer cell line, researchers found that CAR-T cell therapy can effectively inhibit the growth of solid tumors, with the most effective CAR having the highest affinity for the antigen.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Xiaonan Xiang, Jianguo Wang, Di Lu, Xiao Xu
Summary: Tumor-associated macrophages (TAMs) play a significant role in tumor immunotherapies, with potential therapeutic value in enhancing treatment outcomes.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Review
Chemistry, Multidisciplinary
Caiyan Zhao, Xiaoyu Pang, Zuo Yang, Sheng Wang, Hongzhang Deng, Xiaoyuan Chen
Summary: TAMs are key players in tumor progression and can be modulated using nanotechnology-based strategies, such as inhibiting their recruitment, depleting M2-polarized macrophages, and reprogramming them into M1-polarized macrophages. Nanoparticles can also be used to image TAMs for novel treatment options and therapy monitoring.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Immunology
Eric de Sousa, Joana R. Lerias, Antonio Beltran, Georgia Paraschoudi, Carolina Condeco, Jessica Kamiki, Patricia Alexandra Antonio, Nuno Figueiredo, Carlos Carvalho, Mireia Castillo-Martin, Zhe Wang, Dario Ligeiro, Martin Rao, Markus Maeurer
Summary: This article discusses factors associated with the successful outcome of immune checkpoint blockade in patients with solid cancers, including high tumor mutational burden, T-cell recognition of private neoantigens, and explores immune therapy strategies related to T-cell receptors, IFN-gamma, HLA, and other factors.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Xinxin Liu, Cuixia Zheng, Yueyue Kong, Hao Wang, Lei Wang
Summary: In this study, a drug delivery system was developed by loading the adjuvant simvastatin into gold nanocages. This system efficiently utilizes tumor-associated antigens to enhance immune responses and activate T cells through promoting dendritic cell maturation, resulting in individualized immunotherapy.
CHINESE CHEMICAL LETTERS
(2022)
Article
Oncology
Karen Kai-Lin Fang, Jongbok Lee, Ismat Khatri, Yoosu Na, Li Zhang
Summary: The use of allogeneic CAR4-DNTs as adoptive cell therapy for T-cell malignancies is effective. CAR4-DNTs can effectively target T-ALL and PTCL and have superior cytotoxicity compared to empty-vector transduced DNTs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Engineering, Biomedical
Yingmin Li, Yang Luo, Lamei Hou, Zhengjie Huang, Yi Wang, Shaobing Zhou
Summary: A new in situ vaccine composed of acid-responsive liposome-coated polydopamine nanoparticles loaded with resiquimod is designed to enhance the efficacy of immunotherapy. The vaccine can actively target the tumor site, promote photothermal therapy, capture immunogenic cell-death-induced tumor-associated antigens, and activate antigen presentation by dendritic cells (DCs). It effectively activates DC maturation and enhances their effect on cytotoxic T lymphocyte cells, while also inhibiting distant recurrence and metastasis of tumors through immune memory effects.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Oncology
Eva Ellebaek, Aimilia Schina, Henrik Schmidt, Charlotte Aaquist Haslund, Lars Bastholt, Inge Marie Svane, Marco Donia
Summary: This study found that initiation of immunotherapy in summer is associated with prolonged survival in patients with BRAF wild-type melanoma in Denmark.
PIGMENT CELL & MELANOMA RESEARCH
(2023)
Editorial Material
Gastroenterology & Hepatology
Emilie K. Dahl, Osama K. Abed, Jens Kjeldsen, Marco Donia, Inge M. Svane, Anders Dige, Jorgen S. Agnholt, Jacob T. Bjerrum, Jakob B. Seidelin
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Inna M. Chen, Marco Donia, Christopher A. Chamberlain, Agnete W. P. Jensen, Arianna Draghi, Susann Theile, Kasper Madsen, Jane P. Hasselby, Anders Toxvaerd, Estrid Hogdall, Torben Lorentzen, Eva E. Wilken, Poul Geertsen, Inge M. Svane, Julia S. Johansen, Dorte Nielsen
Summary: The combination of ipilimumab, nivolumab, tocilizumab, and SBRT did not meet the expected criteria for treating pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Immunology
Giulia Franciosa, Anders H. Kverneland, Agnete W. P. Jensen, Marco Donia, Jesper V. Olsen
Summary: Cancer survival relies on tumor cells evading immune recognition, but immunotherapy has shown promising results in metastatic cancers. Resistance mechanisms limit efficacy, so understanding the interplay between immune cells and tumors is crucial. Mass spectrometry-based proteomics may provide insights into tumor immunity and cancer immunotherapies, allowing for translational and clinical discoveries.
SEMINARS IN IMMUNOPATHOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Emilie Dahl, Osama Abed, Jorgen Agnholt, Jacob Bjerrum, Anders Dige, Jens Kjeldsen, Inge Svane, Marco Donia, Jakob Seidelin
Summary: This article is linked to Dahl et al papers. To view these articles, visit...
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Oncology
Tine J. Monberg, Troels H. Borch, Inge M. Svane, Marco Donia
Summary: Treatment with tumor-infiltrating lymphocytes (TIL) has been proven to be safe, feasible, and effective for patients with metastatic melanoma. However, its implementation on a larger scale is currently limited due to the lack of regulatory approvals. This review discusses the current knowledge of TIL therapy and addresses the practical, logistic, and economic challenges associated with its widespread implementation.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Arianna Draghi, Mario Presti, Agnete W. P. Jensen, Christopher A. Chamberlain, Benedetta Albieri, Anne-Christine K. Rasmussen, Mads H. Andersen, Michael D. Crowther, Inge Marie Svane, Marco Donia
Summary: Our study demonstrates that exploiting tumor-specific cytotoxic CD4(+) TILs could help overcome resistance to ICB mediated by IFN gamma-signaling loss in MHCIIconst(+) melanomas.
CLINICAL CANCER RESEARCH
(2023)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Thomas Morgan Hulen, Christina Friese, Nikolaj Pagh Kristensen, Joachim Stoltenborg Granhoj, Troels Holz Borch, Marlies J. W. Peeters, Marco Donia, Mads Hald Andersen, Sine Reker Hadrup, Inge Marie Svane, Ozcan Met
Summary: Checkpoint inhibition (CPI) therapy and adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL-based ACT) have shown to be highly effective immunotherapies for metastatic melanoma treatment. In this study, we investigated the changes in TIL qualities when the ex vivo microenvironment of intact tumor fragments were modulated with checkpoint inhibitors targeting PD-1 and CTLA-4. We found that unmodified TILs from CPI-resistant individuals could be produced, were terminally differentiated, and capable of responding to tumor. Furthermore, we confirmed the specificity of TILs to highly responding tumor antigens and identified the contribution of specific CD39(+)CD69(+) terminally differentiated populations.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Andrew Chancellor, Robert Alan Simmons, Rahul C. Khanolkar, Vladimir Nosi, Aisha Beshirova, Giuliano Berloffa, Rodrigo Colombo, Vijaykumar Karuppiah, Johanne M. Pentier, Vanessa Tubb, Hemza Ghadbane, Richard J. Suckling, Keith Page, Rory M. Crean, Alessandro Vacchini, Corinne De Gregorio, Verena Schaefer, Daniel Constantin, Thomas Gligoris, Angharad Lloyd, Miriam Hock, Velupillai Srikannathasan, Ross A. Robinson, Gurdyal S. Besra, Marc W. Van der Kamp, Lucia Mori, Raffaele Calogero, David K. Cole, Gennaro De Libero, Marco Lepore
Summary: Canonical MAIT TCRs with dual reactivity to microbial and self-antigens can recognize MR1 promiscuously, allowing MAIT cell responses in the absence of microbial infection. MAIT TCRs can also crossreact with self-antigens and perform T-helper-like functions in vitro. The promiscuity of MR1 recognition by a canonical MAIT TCR is associated with unique TCR β-chain features enriched in self-reactive MAIT cells of healthy individuals. These findings suggest a broader role of MAIT cells in immune homeostasis and diseases beyond microbial immunosurveillance.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Moon Hee Lee, Jason Theodoropoulos, Jani Huuhtanen, Dipabarna Bhattacharya, Petrus Jarvinen, Sara Tornberg, Harry Nisen, Tuomas Mirtti, Ilona Uski, Anita Kumari, Karita Peltonen, Arianna Draghi, Marco Donia, Anna Kreutzman, Satu Mustjoki
Summary: In this study, we investigated the expanded tumor-infiltrating lymphocytes (TILs) in patients with renal cell carcinoma (RCC) and explored their characteristics and ability to recognize the tumor using experimental and computational tools.
CANCER RESEARCH COMMUNICATIONS
(2023)